These are top 10 stocks traded on the Robinhood UK platform in July
This news is based on a press release statement from PacBio. The company’s products are intended for research purposes only and are not approved for diagnostic procedures. PacBio has advised that forward-looking statements in the press release should not be seen as guarantees of future performance or expansion into the clinical genomics market. Investors interested in following NEO’s performance can access additional InvestingPro financial metrics, including Fair Value analysis and growth indicators, with the platform offering 8 more exclusive ProTips for informed decision-making. Investors interested in following NEO’s performance can access additional InvestingPro financial metrics, including Fair Value analysis and growth indicators, with the platform offering 8 more exclusive ProTips for informed decision-making.
This news is based on a press release statement from PacBio. The company’s products are intended for research purposes only and are not approved for diagnostic procedures. PacBio has advised that forward-looking statements in the press release should not be seen as guarantees of future performance or expansion into the clinical genomics market. Investors interested in following NEO’s performance can access additional InvestingPro financial metrics, including Fair Value analysis and growth indicators, with the platform offering 8 more exclusive ProTips for informed decision-making.
"We are thrilled to welcome Chris to the PacBio Board," stated Christian Henry, President and CEO of PacBio. "His deep expertise in clinical diagnostics and genomics will be invaluable as we continue to expand into the clinical genomics market."
The announcement coincides with the resignation of David Meline from the PacBio Board, effective today. Meline, who has been a board member since 2023, was recognized for his contributions to the company’s strategic direction.
Smith expressed enthusiasm about his new role, saying, "I am honored to join PacBio’s Board at such an exciting time in the company’s journey."
PacBio is recognized for its HiFi long-read sequencing and SBB® short-read sequencing technologies, which are pivotal for research applications in various fields, including human genetics, plant and animal sciences, and microbiology.
The company’s forward-looking statement cautions that actual outcomes could differ due to various risks and uncertainties, advising against undue reliance on these projections.
This news is based on a press release statement from PacBio. The company’s products are intended for research purposes only and are not approved for diagnostic procedures. PacBio has advised that forward-looking statements in the press release should not be seen as guarantees of future performance or expansion into the clinical genomics market.
In other recent news, Neogenomics has experienced a series of significant developments. The company has announced optimistic financial guidance for 2025, projecting revenues between $735 million and $745 million and adjusted EBITDA ranging from $55 million to $58 million. This guidance surpasses the consensus estimate of $728 million in revenue and $54.5 million in adjusted EBITDA. The company’s long-term financial goals include a 12-13% annual revenue increase, primarily driven by its next-generation sequencing testing, expected to grow at roughly 25% per year.
Neogenomics also disclosed a leadership transition with the retirement of CEO Chris Smith and the appointment of Tony Zook. Despite this change, analysts from firms such as TD Cowen, Raymond (NSE:RYMD) James, and Needham maintained positive ratings, expressing confidence in the company’s continued growth and performance. Needham analysts reaffirmed a Buy rating and a $19.00 price target on the company’s shares amidst the leadership transition.
Moreover, NeoGenomics (NASDAQ:NEO) reported notable financial results in the third quarter, with total revenues rising by 10% to $168 million, primarily due to a 14% increase in clinical services revenue. The company’s adjusted EBITDA surged by 305%, reaching $13 million. Benchmark has adjusted its own forecasts in light of this new guidance from Neogenomics, with the firm’s revised 2025 revenue prediction for Neogenomics now standing at $735 million, up from the previous estimate of $719 million.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.